{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Brilanestrant",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.",
    "fdaUniiCode": "9MM2R1A06R",
    "identifier": "C106235",
    "preferredName": "Brilanestrant",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2116"
    ],
    "synonyms": [
      "ARN-810",
      "BRILANESTRANT",
      "Brilanestrant",
      "GDC-0810",
      "RO7056118",
      "SERD ARN-810"
    ]
  }
}